Trial
NCT01194908
Re-expression of ER in Triple Negative Breast Cancers
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Emory University
Collaborators
Novartis; Eisai Inc.
Condition
Breast Cancer
Intervention
Decitabine, LBH589, Tamoxifen
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-01-26